Loss of TSC2 was associated to everolimus response in PDX models of hepatocellular carcinoma [18] and breast cancer patients with low level of LKB1 protein derived greater benefit from everolimus in combination with tamoxifen in the TAMRAD trial [19]. Here, TSC2 is linked to hepatocellular carcinoma.